title: Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma.
abstract: Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is extensively explored in cancers. It functions as an important regulator of cell growth, survival and metabolism. Activation of this pathway also predicts poor prognosis in numerous human malignancies. Drugs targeting this signaling pathway have been developed and have shown preliminary clinical activity. Accumulating evidence has highlighted the important role of PI3K in non-Hodgkin lymphoma (NHL), especially in the disease initiation and progression. Therapeutic functions of PI3K inhibitors in NHL have been demonstrated both in vivo and in vitro. This review will summarize recent advances in the activation of PI3K signaling in different types of NHL and the applications of PI3K inhibitors in NHL treatment.
authors.affiliation: Department of Hematology, Shandong Provincial Hospital affiliated to Shandong University, 324 Jingwu Road, Jinan, Shandong 250021, P,R, China. xinw007@126.com.
authors.forename: Xiaosheng
authors.initials: X
authors.lastname: Fang
authors.forename: Xiangxiang
authors.initials: X
authors.lastname: Zhou
authors.forename: Xin
authors.initials: X
authors.lastname: Wang